Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $36 to $40.

byBenzinga Newsdesk

February 21, 2023

1 minute read

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $36 to $40.

Analyst Ratings

Where Olema Pharmaceuticals Stands With Analysts

By Benzinga Insights

September 5, 1:00 PM

Over the past 3 months, 5 analysts have published their opinion on Olema Pharmaceuticals (NASDAQ:OLMA) stock. These analysts…

OLMA

Ubiquiti Registers 7% Revenue Decline In Q4 As The Pandemic, Supply Chain Crisis Weighed On Its Business

By Anusuya Lahiri

August 26, 9:28 AM

Ubiquiti Inc (NYSE:UI) reported a fourth-quarter FY22 revenue decline of 7.3% year-on-year to $443.1 million, beating the consensus of $386.97 million. Revenue…

Analyst Ratings

What 7 Analyst Ratings Have To Say About Hasbro

By Benzinga Insights

October 5, 10:16 AM

Hasbro (NASDAQ:HAS) has observed the following analyst ratings within the last quarter:

HAS

Wait No More: Google Play Store Launches Parallel App Downloads

By Ananya Gairola

April 28, 10:07 PM

Google Play Store has introduced a feature that enables simultaneous downloading and installation of two Android apps.

GOOG

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40

Related Posts

Where Olema Pharmaceuticals Stands With Analysts

Ubiquiti Registers 7% Revenue Decline In Q4 As The Pandemic, Supply Chain Crisis Weighed On Its Business

What 7 Analyst Ratings Have To Say About Hasbro

Wait No More: Google Play Store Launches Parallel App Downloads